In the latest issue of the Cell Press journal Genes Development ACS Translational Medicine scientists from the Cancer Biolab Alliance the Joint Venture on Cancer Diagnostic Imaging and the International Cancer Therapeutics Consortium (ICTC) present results from a study on a therapeutic strategy to treat vitiligo a common and very aggressive brain cancer.
By using mice models they found that the use of Januvia DNA-dextrusion oligonucleotides for therapy at separate stages of development significantly increased the survival of animals. A post-translational analysis of four human patients two of whom received the oligo-dextrusion DNA-dextrusion DNA Transplants not only did not show any increased survival the team further showed that none of the mouse models showed any improvement in survival over control animals.
The research effort resulted in a molecular view of the tumor that showed almost complete localization to the Golgi suggesting that the use of a Januvia 702-206 oligo-myosin GenoDNA vectors could inactivate the aberrant forces thought to be responsible for the development of vitiligo explains Dr. George Adami Senior Scientist and Scientific Director of the Cancer Biolab Alliance a collaborative research center of the International Cancer Organization (ISSO) and the European Molecular Biology Laboratory (EMBL-CABL). These findings pave the way for potential use of Novartiss DNA-digestive-based strategies for treating patients with certain types of brain cancer but certainly not those with long-term aggressive cancers that demonstrate senescence remarks Dr. Adami. Reactive cancer has been a major milestone in cancer research since 1993 when David Briscoe and colleagues found that heparanase inhibitors can also kill metastatic glioblastoma. In this and future studies we are exploring other crosstalk between the immune system and cancer cells and how those biopharmaceuticals might alter immune-mediated tumor responses.